MSD’s PD-1 inhibitor Keytruda has been approved by the FDA as a treatment for locally advanced unresectable or metastatic biliary tract cancer (BTC) in combination with ch
Shares in Cellectis shot up this morning after the French biotech revealed a wide-ranging alliance with AstraZeneca, which includes $245 million in near-term financial com
GSK has built the case for first-line use of its PD-1 inhibitor Jemperli in endometrial cancer, with new survival data that could help it expand the label for the drug.
With Europe’s premier cancer congress ESMO now finished, we close our coverage with a look at some other important new studies that generated a buzz at the show.
The FDA has started a review of an extension to the labelling for AstraZeneca’s influenza vaccine FluMist Quadrivalent which would allow it to be administered by patients
AstraZeneca will hear back from the FDA in the first quarter of next year about its recent filing of Tagrisso in combination with chemotherapy as a first-line treatment fo